Kryptonite for cancer cells

Mar 19, 2013 by Angela Herring
Mansoor Amiji, Distinguished Professor and Chair of the Department of Pharmaceutical Sciences at Northeastern University. Amiji's field of expertise includes Drug Delivery and Nanomedicine, the application of nanotechnology for medical diagnosis, imagining, and therapy.

(Phys.org) —Every available cancer drug is susceptible to resistance, according to Mansoor Amiji, Distinguished Professor and chair of the Department of Pharmaceutical Sciences. Tumors grow more quickly than blood vessels, so these unruly masses of cells receive very little oxygen and nutrients, which means they know just how to survive under harsh conditions. They make miniature pumps to actively dispel anything that doesn't serve them well (like drugs), and they evade all the checks and balances that normally maintain healthy cell populations.

Each of these supercell powers is coded in the cancer's DNA. In theory, turning off the right genes would turn off the superpowers, according to Amiji. A method called does exactly that. By inhibiting of specific sections of DNA, so-called , or , can shut down the activity of individual genes.

But this is easier said than done. The siRNA molecules are incredibly finicky molecules, which Amiji likened to a picky houseguest who needs everything just so. "They're small, negatively charged, and extremely labile," he said, and they degrade if you so much as breathe on them in the lab. All of these characteristics make it difficult to get them where you want them inside the body.

In a recent paper in the journal Biomaterials, Amiji and collaborators at Novartis Institutes for Biomedical Research present a system that they believe will overcome some of these challenges. Using their expertise in targeted drug delivery, Amiji's team developed a modular system that can be used to deliver siRNA and any standard drug directly to the cancer cells and nowhere else. This work is funded by the 's Alliance for Nanotechnology in Cancer Platform Partnership grant.

"If we really want to take resistance head on, we need to address it in a multifactorial way," said Amiji. The new modular system is just that—a multifaceted approach that simultaneously addresses chemo toxicity and resistance, two of the most difficult challenges facing cancer drug developers.

In the research, spearheaded by Amiji's former graduate student Shanthi Ganesh and current research assistant professor Arun Iyer, the team created a library of carrier complexes, each specialized for certain properties. Some of the complexes are good at carrying negatively charged molecules (like siRNA) through the negatively charged cell membrane, which normally repels them. Other complexes are good at engulfing hydrophobic drugs (which don't dissolve in water), while still others work better with hydrophilic, or
water-loving," drugs.

"It's almost like Lego pieces that you can mix and match to create the right assembly for the right type of payload, and then subsequently target the right area of the body where it needs to be delivered," said Amiji.

The assemblies also dawn molecules that make them act like homing-pigeons in the blood, carrying their messages of cellular destruction to cancer cells alone.

In this research, Amiji's team focused on a molecule called hyaluronic acid, which many cancer cells recognize via specialized receptors on their surface. In the lab, they were able to design systems that delivered drugs and siRNAs directly and solely to cancer cells, wherein 100 percent of the payload was released.

But once they tested the process in live mice, they had less success. That's because two factors that help ensure the complexes will reach their target aren't an issue in the petri dish: plumbing and instructions. If the targeted have too few receptors on their surface, the complexes won't find them in the relatively enormous organismal system. But even if receptor expression is high, blood supply must also be high in the live mouse, or they won't even begin their journey in the first place.

Future researchers will need to balance these factors when using the team's library to develop carriers appropriate for specific drugs and cancer types, Amiji said. But the modularity of their system makes it especially well-suited to deal with a variety of unique challenges. "It allows us to customize this system for the right type of tumor," he explained.

Explore further: Next generation biomarker detects tumour cells and delivers anti-cancer drugs

More information: www.sciencedirect.com/science/… ii/S014296121300118X

add to favorites email to friend print save as pdf

Related Stories

Double-Duty Nanoparticles Overcome Drug Resistance in Tumors

Jun 14, 2007

Cancer cells, like bacteria, can develop resistance to drug therapy. In fact, research suggests strongly that multidrug resistant cancer cells that remain alive after chemotherapy are responsible for the reappearance of tumors ...

Iron key to brain tumor drug delivery

Jun 02, 2011

Brain cancer therapy may be more effective if the expression of an iron-storing protein is decreased to enhance the action of therapeutic drugs on brain cancer cells, according to Penn State College of Medicine researchers.

Recommended for you

A gut reaction

Nov 19, 2014

Queen's University biologist Virginia Walker and Queen's SARC Awarded Postdoctoral Fellow Pranab Das have shown nanosilver, which is often added to water purification units, can upset your gut. The discovery ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

jalmy
1 / 5 (4) Mar 19, 2013
"If the targeted cancer cells have too few receptors on their surface, the complexes won't find them in the relatively enormous organismal system."

Wouldn't you just inject the drug into the tumor with a needle?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.